)
Shares of Suven Life Sciences have moved higher by 6% to Rs 249 on the BSE after the drug firm said it has secured patents in China and South Africa for a drug used in the treatment of neurodegenerative diseases.
“The company secured patents in China and South Africa to its New Chemical Entities (NCE’s) for CNS therapy through mechanism of action – H3 Inverse agonist and these patents are valid until 2031, 2030 and 2031 respectively,” Suven Life Sciences said in a news release.
The granted claims of the patent include the class of selective H3 ligands discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders, it added.
Neurodegenerative diseases include Alzheimer's, Schizophrenia and Parkinson's.
The stock opened at Rs 235 and hit a high of Rs 252 on the BSE. The trading volumes on the counter more than doubled with a combined 1.35 million shares changed hands on the BSE and NSE till 1056 hours.
“The company secured patents in China and South Africa to its New Chemical Entities (NCE’s) for CNS therapy through mechanism of action – H3 Inverse agonist and these patents are valid until 2031, 2030 and 2031 respectively,” Suven Life Sciences said in a news release.
The granted claims of the patent include the class of selective H3 ligands discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders, it added.
Neurodegenerative diseases include Alzheimer's, Schizophrenia and Parkinson's.
The stock opened at Rs 235 and hit a high of Rs 252 on the BSE. The trading volumes on the counter more than doubled with a combined 1.35 million shares changed hands on the BSE and NSE till 1056 hours.
